Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists

G protein-coupled receptors (GPCRs) are attractive targets for pharmaceutical research. With the recent determination of several GPCR X-ray structures, the applicability of structure-based computational methods for ligand identification, such as docking, has increased. Yet, as only about 1% of GPCRs have a known structure, receptor homology modeling remains necessary. In order to investigate the usability of homology models and the inherent selectivity of a particular model in relation to close homologs, we constructed multiple homology models for the A1 adenosine receptor (A1AR) and docked ∼2.2 M lead-like compounds. High-ranking molecules were tested on the A1AR as well as the close homologs A2AAR and A3AR. While the screen yielded numerous potent and novel ligands (hit rate 21% and highest affinity of 400 nM), it delivered few selective compounds. Moreover, most compounds appeared in the top ranks of only one model. These findings have implications for future screens.

[1]  Claudio N. Cavasotto,et al.  Ligand-Steered Modeling and Docking: A Benchmarking Study in Class A G-Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..

[2]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[3]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[4]  M. Givertz,et al.  Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure , 2009, Expert opinion on pharmacotherapy.

[5]  Keizo Yoshida,et al.  Protective effects of FK453, a potent nonxanthine adenosine A1 receptor antagonist, on glycerol‐induced acute renal failure in rats , 1996 .

[6]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[7]  Tudor I. Oprea,et al.  WOMBAT: World of Molecular Bioactivity , 2005 .

[8]  K. Klotz,et al.  2-Chloro-N6-[3H]cyclopentyladenosine ([3HCCPA) —a high affinity agonist radioligand for A1 adenosine receptors , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[10]  K. Jacobson,et al.  125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. , 1994, Molecular pharmacology.

[11]  Barbara Cacciari,et al.  Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.

[12]  A. Bianucci,et al.  QSAR study on a novel series of 8-azaadenine analogues proposed as A1 adenosine receptor antagonists. , 2008, European journal of medicinal chemistry.

[13]  G. V. van Westen,et al.  Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. , 2011, Trends in pharmacological sciences.

[14]  B. Fredholm,et al.  Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  J. Irwin,et al.  Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.

[16]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[17]  Kenneth A Jacobson,et al.  Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.

[18]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[19]  Mathias Wawer,et al.  Similarity-Potency Trees: A Method to Search for SAR Information in Compound Data Sets and Derive SAR Rules , 2010, J. Chem. Inf. Model..

[20]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[21]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[22]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[23]  S. Rivkees,et al.  Identification of the Adenine Binding Site of the Human A1 Adenosine Receptor* , 1999, The Journal of Biological Chemistry.

[24]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[25]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[26]  A. Sali,et al.  Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.

[27]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[28]  George A. Kaminski,et al.  Force Field Validation Using Protein Side Chain Prediction , 2002 .

[29]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[30]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[31]  M. Williams,et al.  [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.

[32]  I. Kuntz,et al.  Matching chemistry and shape in molecular docking. , 1993, Protein engineering.

[33]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[34]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[35]  Michael M. Mysinger,et al.  Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4 , 2012, Proceedings of the National Academy of Sciences.

[36]  J. Ramachandran,et al.  Structure and Function of G Protein Coupled Receptors , 1990, Pharmaceutical Research.

[37]  M. Lohse,et al.  2-Chloro-N 6 -( 3 H)cyclopentyladenosine (( 3 H)CCPA) - a high affinity agonist radio Iigand for A 1 adenosine receptors , 1989 .

[38]  Kenneth Jones,et al.  Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.

[39]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[40]  A. Sali,et al.  Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.

[41]  K. Dickstein,et al.  Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure , 2009, Circulation. Heart failure.

[42]  M. Givertz,et al.  Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. , 2009, Expert opinion on pharmacotherapy.

[43]  K. Jacobson,et al.  New Insights for Drug Design from the X-Ray Crystallographic Structures of G-Protein-Coupled Receptors , 2012, Molecular Pharmacology.

[44]  Brian K Shoichet,et al.  Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[45]  I. Kuntz,et al.  Ligand solvation in molecular docking , 1999, Proteins.

[46]  B. Honig,et al.  A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.

[47]  Peter Kolb,et al.  The golden age of GPCR structural biology: any impact on drug design? , 2011, Angewandte Chemie.

[48]  Thierry Kogej,et al.  Comparison of Molecular Fingerprint Methods on the Basis of Biological Profile Data , 2009, J. Chem. Inf. Model..

[49]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[50]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.